<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765644</url>
  </required_header>
  <id_info>
    <org_study_id>18IC4757</org_study_id>
    <nct_id>NCT04765644</nct_id>
  </id_info>
  <brief_title>Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment</brief_title>
  <acronym>ASCENT</acronym>
  <official_title>Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment (ASCENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single centre, placebo controlled, blinded (participant, investigator, outcome assessor)&#xD;
      trial to evaluate the effects of COX-2 inhibition with celecoxib on endothelial function in&#xD;
      healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To perform a systemic analysis of how COX-2 inhibition by celecoxib&#xD;
      affects vascular function and 'omic biomarkers including those associated with the&#xD;
      COX-2/prostacyclin/ADMA axis in healthy male volunteers&#xD;
&#xD;
      Secondary Objective: To investigate how this is altered by L-arginine supplementation&#xD;
&#xD;
      Methods: A single centre, double blind, placebo controlled trial will be carried out in&#xD;
      healthy male volunteers between 18 and 40 years of age. In phase 1, participants will be&#xD;
      blinded and randomised to receive either Celecoxib 200mgBD for 7 days or placebo. The primary&#xD;
      endpoint is endothelial function measured by EndoPAT. In Phase 2, the same participants will&#xD;
      receive either Celecoxib 200mgBD for 7 days + 10g L-arginine supplementation or placebo + 10g&#xD;
      L-arginine supplementation to see if L-arginine can reverse any endothelial dysfunction&#xD;
      caused by Celecoxib. Secondary outcomes will include measurement of 'omic biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy male volunteers will be blinded and randomized to 7 days' treatment with celecoxib (200mg bd) or placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>7 days</time_frame>
    <description>Measured using EndoPAT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sitting blood pressure</measure>
    <time_frame>7 days</time_frame>
    <description>Participants will record their blood pressure daily using a home monitoring device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Biomarkers</measure>
    <time_frame>7 days</time_frame>
    <description>Measured using mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 1: Twenty volunteers will receive celecoxib 200 mg, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.&#xD;
In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 1: Twenty volunteers will receive a placebo capsule, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.&#xD;
In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Two 200 mg capsules per day (400 mg/day) for 7 days</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules/day for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>L-arginine + placebo</intervention_name>
    <description>L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>L-arginine + celecoxib</intervention_name>
    <description>L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No abnormal findings on medical history, screening physical examination, hematology,&#xD;
             biochemistry, urinalysis (including specific gravity), and vital signs (sitting blood&#xD;
             pressure, sitting pulse rate, sitting respiratory rate and body temperature) within 2&#xD;
             weeks of commencement of the study.&#xD;
&#xD;
          -  Normal fasting lipid profile&#xD;
&#xD;
          -  Non-smoking&#xD;
&#xD;
          -  Clear venous access in upper limbs&#xD;
&#xD;
          -  BMI: 18-30&#xD;
&#xD;
          -  No history or signs of drug abuse&#xD;
&#xD;
          -  No other medication 4 weeks before or during the study&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of allergy to NSAIDS or arginine&#xD;
&#xD;
          -  Significant medical conditions&#xD;
&#xD;
          -  Pulse rate &lt;50 bpm&#xD;
&#xD;
          -  Sitting systolic blood pressure &lt;80 or &gt;160 mmHg&#xD;
&#xD;
          -  Sitting diastolic pressure &lt;60 or &gt;100 mmHg&#xD;
&#xD;
          -  Baseline endothelial dysfunction (as defined by EndoPAT; LnRHI &lt;0.51)&#xD;
&#xD;
          -  Participation in other clinical study 8 weeks before or during the study&#xD;
&#xD;
          -  Donation of blood 8 weeks before or during the study&#xD;
&#xD;
          -  Those on medication that cannot be discontinued&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male Volunteers</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Mitchell, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Collins, Professor</last_name>
    <phone>+44 (0)20 7351 8112</phone>
    <email>peter.collins@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Mitchell, Professor</last_name>
    <email>j.a.mitchell@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>w12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricky Vaja</last_name>
      <email>Ascent@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS, Warner TD, Nicolaou A, Herschman HR, Mitchell JA. LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One. 2013 Jul 9;8(7):e69524. doi: 10.1371/journal.pone.0069524. Print 2013.</citation>
    <PMID>23874970</PMID>
  </reference>
  <reference>
    <citation>Kirkby NS, Chan MV, Zaiss AK, Garcia-Vaz E, Jiao J, Berglund LM, Verdu EF, Ahmetaj-Shala B, Wallace JL, Herschman HR, Gomez MF, Mitchell JA. Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways. Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):434-9. doi: 10.1073/pnas.1517642113. Epub 2015 Dec 28.</citation>
    <PMID>26712011</PMID>
  </reference>
  <reference>
    <citation>Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008 Jan 19;371(9608):270-3. doi: 10.1016/S0140-6736(08)60137-3. Review.</citation>
    <PMID>18207021</PMID>
  </reference>
  <reference>
    <citation>Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15782-7. doi: 10.1073/pnas.1218880110. Epub 2013 Sep 3.</citation>
    <PMID>24003163</PMID>
  </reference>
  <reference>
    <citation>Ahmetaj-Shala B, Kirkby NS, Knowles R, Al'Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie L, Armstrong PC, Nüsing RM, Tomlinson JA, Warner TD, Leiper J, Mitchell JA. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation. 2015 Feb 17;131(7):633-42. doi: 10.1161/CIRCULATIONAHA.114.011591. Epub 2014 Dec 9.</citation>
    <PMID>25492024</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSAID</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>COX-2</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>biomarker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

